Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer

OBJECTIVE: Despite advances in cervical cancer prevention and diagnosis, outcomes for patients given a diagnosis of advanced and recurrent disease are poor. In the GOG240 trial, the addition of bevacizumab to paclitaxel-topotecan or paclitaxel-cisplatin has been shown to prolong survival compared wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosen, Virginia M., Guerra, Ines, McCormack, Mary, Nogueira-Rodrigues, Angélica, Sasse, Andre, Munk, Veronica C., Shang, Aijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Cervical Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499964/
https://www.ncbi.nlm.nih.gov/pubmed/28448304
http://dx.doi.org/10.1097/IGC.0000000000001000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499964/
https://www.ncbi.nlm.nih.gov/pubmed/28448304
http://dx.doi.org/10.1097/IGC.0000000000001000

Ejemplares similares